^
Association details:
| Biomarker: | ZNF479 mutation + TMB-H |
|---|---|
| Cancer: | Lung Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1738P - Association of ZNF479 mutation with tumor mutation burden and survival in lung cancer patients treated with immune checkpoint inhibitors
Published date:
09/13/2021
Excerpt:
ZNF479 mutation is associated with higher TMB (p=0.044), significantly longer PFS(16.0 vs 4.2 months; HR, 0.1; P=0.006) and longer OS (23.3 vs 6.8 months; p=0.032) in lung cancer patients treated with ICIs.
